---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003292"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:55:03.050335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion reports preclinical data showing SIL204 reaches metastatic sites in pancreatic cancer model

## Summary
- Subcutaneous SIL204 (5 mg/mouse) distributed to liver, peritoneum, lung in Panc-1 KRAS G12D metastatic model.
- Tumor burden reduced significantly (p<0.01) in peritoneum, lung, intestine; liver showed measurable reduction.
- Data supports dual-route strategy: intratumoral for primary tumor, systemic for metastases.
- Phase 2/3 trial on track for H1 2026; regulatory submissions planned Q4 2025 and Q1 2026.

## SEC filing metadata
- accession: 0001178913-25-003292
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003292/0001178913-25-003292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003292/zk2533776.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003292
- JSON: https://secwatch.observer/filing/0001178913-25-003292.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.